AstraZeneca commences patent infringement litigation against IVAX
13-Mar-2006
The lawsuit is in response to an Abbreviated New Drug Application filed by IVAX with the US Food and Drug Administration regarding IVAX's intent to market a generic version of AstraZeneca's NEXIUM in the US prior to the expiration of five AstraZeneca Patents: 5,714,504; 5,877,192; 6,369,085; 6,428,810; and 6,875,872. The expiration dates for these patents range from 2014 through to 2019.
Most read news
Topics
Teva Pharmaceutical
patents
AstraZeneca
patent infringement
Nexium
magnesium
laboratories
IVAX Pharmaceuticals
food
Organizations
IVAX Pharmaceuticals
Teva
AstraZeneca
Teva
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.